EUFLEXXA

EUFLEXXA is a non-avian-derived hyaluronic acid product specifically designed to alleviate knee pain associated with osteoarthritis. It is the first and only hyaluronic acid in the U.S. approved for this indication that is not sourced from avian origins, reducing the risk of avian-related reactions.

Ferring Pharmaceuticals acquired EUFLEXXA in July 2005 through the purchase of Savient Pharmaceuticals, Inc.’s global biologics manufacturing business. This strategic acquisition expanded Ferring’s portfolio into the orthopedics market, complementing its existing therapeutic focus areas.

Following the acquisition, Ferring launched EUFLEXXA in November 2005, introducing a three-injection treatment regimen for patients unresponsive to conservative non-pharmacologic therapies or simple analgesics. In April 2006, the U.S. Food and Drug Administration (FDA) approved a supplement allowing EUFLEXXA to be stored at room temperature, improving convenience for both physicians and patients.

In December 2020, Ferring Pharmaceuticals secured preferred access for EUFLEXXA through CVS Health and Aetna formularies, further increasing its availability for patients seeking relief from knee osteoarthritis pain.